## REMARKS

In response to the March 28, 2002 Notice to File Missing Parts of Nonprovisional Application, Applicants submit herein an executed Combined Declaration and Power of Attorney; payment of the $130.00 surcharge for filing late (Check #14482); an initial computer readable form (CRF) copy of the "Sequence Listing"; an initial paper copy of the "Sequence Listing"; payment of the $1,960.00 Petition fee (Check #14481) and return postcard. No new matter has been added. A statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 38 C.F.R. §§ 1.821-1.825 is also included. The Specification has been amended to insert the sequence listing. The response is due on or before October 28, 2002 with a five-month extension of time.

The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311 (Reference No.21402-213 (Cura 513).

## CONCLUSION

If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Dated: October 28, 2002

Ivor R. Elrifi, Reg. No. 39,529
Cynthia. A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

***Version with Markings to Show Changes Made***

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

    (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7, and] 10;

    (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;

    (c) an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10; and

    (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10 wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

2 The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10.

3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO: [1, 3, 4, 6, 8, and] 9.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

    (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10;

(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;

(c) an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10;

(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NO: [2, 5, 7 and] 10, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;

(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NO: [2, 5, 7 and] 10, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and

(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).

8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO: [1, 3, 4, 6, 8, and] 9.

9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

(a) a nucleotide sequence selected from the group consisting of SEQ ID NO: [1, 3, 4, 6, 8, and] 9;

(b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NO: [1, 3, 4, 6, 8, and] 9, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;

(c) a nucleic acid fragment of (a); and

(d) a nucleic acid fragment of (b).

10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NO: [1, 3, 4, 6, 8, and] 9, or a complement of said nucleotide sequence.

40. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NO: [2, 5, 7 and] 10, or a biologically active fragment thereof.